Daily non-political popular news in brief.

Ghost authorship of industry funded drug trials is common

Ghost authorship is the failure to name, as an author, an individual who has made a substantial contribution to a scientific article. A study of 44 industry-initiated trials from Denmark in the 1990s found evidence of ghost authorship for 33 trials, which increased to 40 if a person qualifying for authorship was just acknowledged rather than being named as an author.

Read more »

Keywords: ghost, authorship, industry, funded, drug, trials, trial

« Previous | Next »

Similar news on "Ghost authorship of industry funded drug trials is common":

1. New agreement questions NHS relation with industry
   11-16-2006 · EurekAlert!
   The Department of Health's new clinical trials agreement raises questions about the NHS's relation with the drug industry, says an editorial published in BMJ Online today.Following the tragedy of the TGN1412 trial, the Department of Health announced last month that a model clinical trials agreement has been finalised. This provides a template that can be used by all NHS trusts for any clinical trial, without modification.
   Similar news · Read more »
   
2. Minimally invasive device shows promise in treating female urinary incontinence
   05-22-2007 · EurekAlert!
   A minimally invasive device for treating recurrent stress urinary incontinence in women has been shown to be safe and effective in early clinical trials and is now under review by the US Food and Drug Administration (FDA), says Emory University School of Medicine urologist and trial co-principal investigator Niall Galloway, MD.
   Similar news · Read more »
   
3. Taking the wraps off drug safety data from clinical trials
   03-06-2007 · EurekAlert!
   A new analysis by researchers at the Harvard School of Public Health (HSPH) and Brigham and Women's Hospital (BWH) of laws and regulations governing public disclosure of clinical trial data submitted to the Food and Drug Administration suggests changes should be made to the way the FDA implements its policy regarding the confidentiality of those data.
   Similar news · Read more »
   
4. New study suggests promising drug combinations for sleeping sickness
   12-08-2006 · EurekAlert!
   Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.
   Similar news · Read more »
   
5. Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
   01-31-2008 · EurekAlert!
   Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of The Lancet.
   Similar news · Read more »
   
6. Drug industry increasingly influences breast cancer research
   02-26-2007 · EurekAlert!
   Breast cancer treatment trials supported by the pharmaceutical industry are more likely to report positive results than non-sponsored studies, according to a study to be published in the April 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
   Similar news · Read more »
   
7. The Lancet publishes details on two studies of adult male circumcision to prevent HIV
   02-22-2007 · EurekAlert!
   Two papers in the February 24 issue of The Lancet provide detailed analyses of two NIAID-funded clinical trials of adult male circumcision in Kenya and Uganda. In the trial of 2,784 HIV-negative men in Kisumu, Kenya, the investigators found the rate of HIV acquisition in circumcised men to be 53 percent lower than in uncircumcised men. Investigators in the trial of 4,996 HIV-negative men in Rakai, Uganda, report that HIV acquisition was reduced by 51 percent in circumcised men.
   Similar news · Read more »
   
8. Safety of new microbicide for HIV prevention to be tested in young women in US trial
   07-09-2007 · EurekAlert!
   In an effort to help stem the tide of the HIV/AIDS epidemic, particularly in women, researchers have launched a clinical safety trial of a topical vaginal microbicide with a unique molecular structure that holds promise for preventing the sexual transmission of HIV. The Microbicide Trials Network is leading the NIH-funded study in which VivaGel is being tested for the first time in sexually active young women to determine its safety, acceptability and ease of use.
   Similar news · Read more »
   
9. Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
   01-31-2008 · EurekAlert!
   Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
   Similar news · Read more »
   
10. Positive results more likely from industry-funded breast cancer trials
    02-26-2007 · EurekAlert!
    Industry-funded studies of breast cancer therapies are more likely to report positive results than non-pharmaceutical funded studies, researchers from the University of North Carolina at Chapel Hill and the Dana Farber Cancer Institute have found. In addition, significant differences exist in the design and nature of clinical trials supported by the pharmaceutical industry compared to trials without industry involvement.
    Similar news · Read more »